Contrasting ProKidney (PROK) and The Competition

ProKidney (NASDAQ:PROK – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare ProKidney to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ProKidney and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney 1 0 2 1 2.75
ProKidney Competitors 9931 15324 45730 1605 2.54

ProKidney presently has a consensus target price of $10.00, suggesting a potential upside of 830.23%. As a group, “Biotechnology” companies have a potential upside of 134.12%. Given ProKidney’s stronger consensus rating and higher probable upside, research analysts plainly believe ProKidney is more favorable than its competitors.

Volatility and Risk

ProKidney has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, ProKidney’s competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Valuation & Earnings

This table compares ProKidney and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ProKidney $890,000.00 -$68.99 million -1.79
ProKidney Competitors $715.39 million $10.31 million -18.32

ProKidney’s competitors have higher revenue and earnings than ProKidney. ProKidney is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ProKidney and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProKidney -13,326.71% N/A -35.31%
ProKidney Competitors -12,319.70% -407.93% -30.95%

Summary

ProKidney beats its competitors on 8 of the 13 factors compared.

About ProKidney

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.